[1] [1] CITRIN D E. Recent developments in radiotherapy[J]. The New England Journal of Medicine, 2017, 377(11): 1065-1075.

[3] [3] VIALLARD C, LARRIVEE B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets[J]. Angiogenesis, 2017, 20(4): 409-426.

[4] [4] PUEYO G, MESIA R, FIGUERAS A, et al. Cetuximab may inhib-it tumor growth and angiogenesis induced by ionizing radiation: a preclinical rationale for maintenance treatment after radiotherapy[J]. The Oncologist, 2010, 15(9): 976-986.

[5] [5] JUNG J W, HWANG S Y, HWANG J S, et al. Ionising radiation induces changes associated with epithelial-mesenchymal transdif-ferentiation and increased cell motility of A549 lung epithelial cells[J]. European Journal of Cancer, 2007, 43(7): 1214-1224.

[6] [6] MOREIN D, ERLICHMAN N, BEN-BARUCH A. Beyond cell motility: the expanding roles of chemokines and their receptors in malignancy[J]. Frontiers in Immunology, 2020, 11: 952.

[7] [7] KOUKOURAKIS M I, GIATROMANOLAKI A, SIVRIDIS E, et al. Squamous cell head and neck cancer: evidence of angiogenic regeneration during radiotherapy[J]. Anticancer Research, 2001,21(6B): 4301-4309.

[9] [9] KOUKOURAKIS M I, KOUKOURAKIS I M, ARELAKI S, et al. Angiogenic regeneration de.nes loco-regional recurrence fol-lowing pre-operative radio-chemotherapy for rectal cancer: a pilot study[J]. Molecular Biology Reports, 2019, 46(2): 2147-2152.

[10] [10] MARQUES F G, POLI E, MALAQUIAS J, et al. Low doses of ionizing radiation activate endothelial cells and induce angiogen-esis in peritumoral tissues[J]. Radiotherapy and Oncology, 2019,141: 256-261.

[11] [11] ZHU H, ZHANG S. Hypoxia inducible factor-1α/vascular endo-thelial growth factor signaling activation correlates with response to radiotherapy and its inhibition reduces hypoxia-induced an-giogenesis in lung cancer[J]. Journal of Cellular Biochemistry, 2018, 119(9): 7707-7718.

[12] [12] SOROLLA M A, PARISI E, SOROLLA A. Determinants of sen-sitivity to radiotherapy in endometrial cancer[J]. Cancers, 2020,12(7): 1906.

[13] [13] BANYS-PALUCHOWSKI M, WITZEL I, RIETHDORF S, et al. The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer[J]. Breast Cancer Research and Treatment, 2018, 172(1): 93-104.

[14] [14] ANOOPKUMAR-DUKIE S, CONERE T, HOUSTON A, et al. The COX-2 inhibitor NS398 selectively sensitizes hypoxic HeLa cells to ionising radiation by mechanisms both dependent and independent of COX-2[J]. Prostaglandins & Other Lipid Media-tors, 2020, 148: 106422.

[15] [15] MITRYAYEVA N A, GREBINYK L V, UZLENKOVA N E. In-fluence of combined action of X-radiation and cyclooxygenase-2-meloxivet inhibitor on VEGF and PGE-2 content in blood of rat-tumor carriers[J]. Problemy Radiatsiinoi Medytsyny Ta Ra-diobiolohii, 2019, 24: 261-269.

[16] [16] KOVACS B, VAJDA E, NAGY E E. Regulatory effects and in-teractions of the Wnt and OPG-RANKL-RANK signaling at the bone-cartilage interface in osteoarthritis[J]. International Journal of Molecular Sciences, 2019, 20(18): 4653.

[17] [17] LIY, SUN R, ZOU J, et al. Dual roles of the AMP-activated pro-tein kinase pathway in angiogenesis[J]. Cells, 2019, 8(7): 752.

[18] [18] HOLOTIUK V V, KRYZHANIVSKA A Y, CHURPIY I K, et al. Role of nitric oxide in pathogenesis of tumor growth and its pos-sible application in cancer treatment[J]. Experimental Oncology, 2019, 41(3): 210-215.

[19] [19] WEI J L, WANG B, WANG H H, et al. Radiation-induced nor-mal tissue damage: oxidative stress and epigenetic mechanisms[J]. Oxidative Medicine and Cellular Longevity, 2019, 2019: 3010342.

[20] [20] SHARIFPANAH F, ALI E H, WARTENBERG M, et al. The milk thistle (Silybum marianum) compound silibinin stimulates leukopoiesis from mouse embryonic stem cells[J]. Phytotherapy Research : PTR, 2019, 33(2): 452-460.

[21] [21] MARTíNEZ-LARA E, PE.A A, CALAHORRA J, et al. Hydroxy-tyrosol decreases the oxidative and nitrosative stress levels and promotes angiogenesis through HIF-1 independent mechanisms in renal hypoxic cells[J]. Food & Function, 2016, 7(1): 540-548.

[22] [22] MASOUD G N, LI W. HIF-1α pathway: role, regulation and in-tervention for cancer therapy[J]. Acta Pharmaceutica Sinica B, 2015, 5(5): 378-389.

[23] [23] ALIQUE M, SANCHEZ-LOPEZ E, BODEGA G, et al. Hypoxia-inducible factor-1α: the master regulator of endothelial cell senes-cence in vascular aging[J]. Cells, 2020, 9(1): 195.

[24] [24] ZHU Y, LIU X, ZHAO P, et al. Celastrol suppresses glioma vas-culogenic mimicry formation and angiogenesis by blocking the PI3K/Akt/mTOR signaling pathway[J]. Frontiers in Pharmacology, 2020, 11: 25.

[25] [25] KO E, BAEK S, KIM J, et al. Antitumor activity of combination therapy with metformin and trametinib in non-small cell lung cancer cells[J]. Development & Reproduction, 2020, 24(2): 113-123.

[26] [26] THOMAS R P, NAGPAL S, IV M, et al. Macrophage exclusion after radiation therapy (MERT): a first in human phase I/II trial using a CXCR4 inhibitor in glioblastoma[J]. Clinical Cancer Re-search: an O.cial Journal of the American Association for Cancer Research, 2019, 25(23): 6948-6957.

[27] [27] VENKATESULU B P, MAHADEVAN L S, ALIRU M L, et al. Radiation-induced endothelial vascular injury: a review of possible mechanisms[J]. JACC: Basic to Translational Science, 2018,3(4): 563-572.

[28] [28] ZHENG Y F, LIU L, CHEN C, et al. The extracellular vesicles secreted by lung cancer cells in radiation therapy promote endo-thelial cell angiogenesis by transferring miR-23a[J]. PeerJ, 2017,5:e3627.

[29] [29] MO F, XUYW, ZHANG J L, et al. Effects of hypoxia and radiation-induced exosomes on migration of lung cancer cells and angiogenesis of umbilical vein endothelial cells[J]. Radiation Research, 2020, 194(1): 71-80.

[30] [30] MAW L, LIU R, HUANG L H, et al. Impact of polymorphisms in angiogenesis-related genes on clinical outcomes of radiotherapy in patients with nasopharyngeal carcinoma[J]. Clinical Experimen-tal Pharmacology Physiology, 2017, 44(5): 539-548.

[31] [31] MARQUES F G, CARVALHO L, SOUSA J S, et al. Low doses of ionizing radiation enhance angiogenesis and consequently acceler-ate post-embryonic development but not regeneration in zebra.sh[J]. Scienti.c Reports, 2020, 10(1): 3137.

[32] [32] JABBARI N, NAWAZ M, REZAIE J. Bystander effects of ion-izing radiation: conditioned media from X-ray irradiated MCF-7 cells increases the angiogenic ability of endothelial cells[J]. Cell Communication and Signaling, 2019, 17(1): 165.

[33] [33] RODRIGUEZ-RUIZ M E, VITALE I, HARRINGTON K J, et al. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment[J]. Nature Immunology, 2020,21(2): 120-134.

[34] [34] FEDELE V, MELISI D. Permissive state of EMT: the role of im-mune cell compartment[J]. Frontiers in Oncology, 2020, 10: 587.

[35] [35] LUND M E, CAMPBELL D H, WALSH B J. The role of glypi-can-1 in the tumour microenvironment[J]. Advances in Experi-mental Medicine and Biology, 2020, 1245: 163-176.

[36] [36] CHEN X, ZHANG H, ZHU H, et al. Endostatin combined with radiotherapy suppresses vasculogenic mimicry formation through inhibition of epithelial-mesenchymal transition in esophageal cancer[J]. Tumour Biology: The Journal of The International So-ciety for Oncodevelopmental Biology and Medicine, 2016, 37(4): 4679-4688.

[37] [37] CHEN Z, XU X H. Combining antiangiogenic therapy and radia-tion in nasopharyngeal carcinoma[J]. Saudi Medical Journal, 2015, 36(6): 659-664.

[38] [38] URIBESALGO I, HOFFMANN D, ZHANG Y, et al. Apelin in-hibition prevents resistance and metastasis associated with anti-angiogenic therapy[J]. EMBO Molecular Medicine, 2019, 11(8): e9266.

[39] [39] SIEMANN D W, CHAPLIN D J, HORSMAN M R. Realizing the potential of vascular targeted therapy: the rationale for combining vascular disrupting agents and anti-angiogenic agents to treat can-cer[J]. Cancer Investigation, 2017, 35(8): 519-534.

[40] [40] CHEN LT, OH DY, RYU M H, et al. Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction can-cer: a systematic review[J]. Cancer Research and Treatment: O.-cial Journal of Korean Cancer Association, 2017, 49(4): 851-868.

[41] [41] ALASVAND M, ASSADOLLAHI V, AMBRA R, et al. Antian-giogenic e.ect of alkaloids[J]. Oxidative Medicine and Cellular Longevity, 2019, 2019: 9475908.

[42] [42] CHAO W R, AMIN K, SHI Y, et al. SR16388: a steroidal anti-angiogenic agent with potent inhibitory e.ect on tumor growth in vivo[J]. Angiogenesis, 2011, 14(1): 1-16.

[43] [43] MATSUMOTO S, BATRA S, SAITO K, et al. Antiangiogenic agent sunitinib transiently increases tumor oxygenation and sup-presses cycling hypoxia[J]. Cancer Research, 2011, 71(20): 6350-6359.

[44] [44] LIN Z, ZHANG Q, LUO W. Angiogenesis inhibitors as therapeutic agents in cancer: challenges and future directions[J]. European Journal of Pharmacology, 2016, 793: 76-81.

[45] [45] LI S, SHEN L. Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists[J]. Journal of Can-cer, 2020, 11(17): 5056-5068.

[46] [46] LIU G, WANG C, E M. Mechanism and prospect of radiotherapy combined with apotatinib in the treatment of non-small cell lung cancer[J]. Chinese Journal of Lung Cancer, 2017, 20(12): 847-851.

[47] [47] GUIPAUD O, JAILLET C, CLEMENT-COLMOU K, et al. The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy[J]. The British Journal of Radiology, 2018, 91(1089): 20170762.

[48] [48] WU J B, TANG Y L, LIANG X H. Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy[J]. Oncotargets and Therapy, 2018, 11: 6901-6909.

[49] [49] BLOMBERG A J, NYHAN M M, BIND M A, et al. The role of ambient particle radioactivity in inflammation and endothelial function in an elderly cohort[J]. Epidemiology, 2020, 31(4): 499-508.

[50] [50] GU X, CUN Y, LI M, et al. Human apurinic/apyrimidinic endo-nuclease siRNA inhibits the angiogenesis induced by X-ray ir-radiation in lung cancer cells[J]. International Journal of Medical Sciences, 2013, 10(7): 870-882.

[51] [51] TEICHER B A, HOLDEN S A, ARA G, et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy[J]. International Journal of Cancer, 1995, 61(5): 732-737.

[52] [52] LIANG LJ, HU C X, WENYX, et al. Apatinib combined with local irradiation leads to systemic tumor control via reversal of immunosuppressive tumor microenvironment in lung cancer[J]. Cancer Research and Treatment: O.cial Journal of Korean Cancer Association, 2020, 52(2): 406-418.

[53] [53] ANTHONY C, MLADKOVA-SUCHY N, ADAMSON D C. The evolving role of antiangiogenic therapies in glioblastoma multi-forme: current clinical signi.cance and future potential[J]. Expert Opinion on Investigational Drugs, 2019, 28(9): 787-797.

[54] [54] CUI X, SONG P, ZHANG L. New advances in the treatment for small cell lung cancer[J]. Chinese Journal of Lung Cancer, 2019,22(6): 355-362.

[55] [55] KANTHOU C, TOZER G. Targeting the vasculature of tumours: combining VEGF pathway inhibitors with radiotherapy[J]. The British Journal of Radiology, 2019, 92(1093): 20180405.

[56] [56] AHN P H, MACHTAY M, ANNE P R, et al. Phase I trial using induction ciplatin, docetaxel, 5-FU and erlotinib gollowed by cis-platin, bevacizumab and erlotinib with concurrent radiotherapy for advanced head and neck cancer[J]. American Journal of Clinical Oncology, 2018, 41(5): 441-446.

[57] [57] YOO D S, KIRKPATRICK J P, CRACIUNESCU O, et al. Pro-spective trial of synchronous bevacizumab, erlotinib, and concur-rent chemoradiation in locally advanced head and neck cancer[J]. Clinical Cancer Research, 2012, 18(5): 1404-1414.

[58] [58] HAAS R L M, GELDERBLOM H, SLEIJFER S, et al. A phase I study on the combination of neoadjuvant radiotherapy plus pa-zopanib in patients with locally advanced soft tissue sarcoma of the extremities[J]. Acta Oncologica (Stockholm, Sweden), 2015,54(8): 1195-1201.

[59] [59] CABEZAS-CAMARERO S, PUENTE J, MANZANO A, et al. Renal cell cancer metastases to esophagus and stomach success-fully treated with radiotherapy and pazopanib[J]. Anti-Cancer Drugs, 2015, 26(1): 112-116.

[60] [60] VISWANATHAN A N, MOUGHAN J, MILLER B E, et al. NRG Oncology/RTOG 0921: a phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endome-trial cancer[J]. Cancer, 2015, 121(13): 2156-2163.

[61] [61] CHEN S W, LIN L C, KUO Y C, et al. Phase 2 study of com-bined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma[J]. International Journal of Radiation Oncology?Biology?Physics, 2014, 88(5): 1041-1047.

[62] [62] BAO Y, PENG F, ZHOU Q C, et al. Phase II trial of recombinant human endostatin in combination with concurrent chemoradio-therapy in patients with stage III non-small-cell lung cancer[J]. Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 2015, 114(2): 161-166.

[63] [63] ZHAI Y, HUI Z, WANG J, et al. Concurrent erlotinib and radio-therapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study[J]. Diseases of the Esophagus 2013, 26(5): 503-509.

[64] [64] Common terminology criteriafor adverse events (CTCAE) version 5.0[S]. Waltham, MA, U.S. Department of Health and Human Services, 2017.

[65] [65] MAW L, LIU R, HUANG L H, et al. Impact of polymorphisms in angiogenesis-related genes on clinical outcomes of radiotherapy in patients with nasopharyngeal carcinoma[J]. Clinical and Experi-mental Pharmacology & Physiology, 2017, 44(5): 539-548.

[66] [66] CAI J, ZHENG J, SHEN J, et al. A radiomics model for predicting the response to bevacizumab in brain necrosis after radiotherapy[J]. Clinical Cancer Research: an O.cial Journal of the American Association for Cancer Research, 2020, 26(20): 5438-5447.

[67] [67] MEHTA R K, PAL S, KONDAPI K, et al. Low dose Hsp90 inhibi-tor selectively radiosensitizes HNSCC and pancreatic xenografts[J]. Clinical Cancer Research: an O.cial Journal of the American Association for Cancer Research, 2020, 26(19): 5246-5257.

[69] [69] KICKINGEREDER P, BRUGNARA G, HANSEN M B, et al. Noninvasive characterization of tumor angiogenesis and oxy-genation in bevacizumab-treated recurrent glioblastoma by using dynamic susceptibility MRI: secondary analysis of the European Organization for Research and Treatment of Cancer 26101 Trial[J]. Radiology, 2020, 297(1): 164-175.